Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent ...

Goldman Sachs is saying good things about this blue chip stock. The post 1 big reason to buy CSL shares now appeared first on ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00.

Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of ...

Learn More Now could be the time to pounce on CSL Ltd (ASX: CSL) shares. That's the view of analysts at Goldman Sachs, which have just initiated coverage on the company. CSL is a global ...

Learn More CSL Ltd (ASX: CSL) shares are trading at $280.30 on Tuesday, up 0.11% at the time of writing. The ASX 200 healthcare giant is among many listed companies that have released their ...